879 related articles for article (PubMed ID: 31841714)
1. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
2. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
3. Ultra-sensitive
Vendrell JA; Mazieres J; Senal R; Rouquette I; Quantin X; Pujol JL; Roch B; Bouidioua A; Godreuil S; Coyaud E; Brousset P; Solassol J
Clin Cancer Res; 2019 Jul; 25(14):4280-4289. PubMed ID: 30936123
[TBL] [Abstract][Full Text] [Related]
4. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
[TBL] [Abstract][Full Text] [Related]
5. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
[TBL] [Abstract][Full Text] [Related]
6. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes.
Ye L; Mesbah Ardakani N; Thomas C; Spilsbury K; Leslie C; Amanuel B; Millward M
Pathol Oncol Res; 2020 Oct; 26(4):2371-2379. PubMed ID: 32506395
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Leduc C; Merlio JP; Besse B; Blons H; Debieuvre D; Bringuier PP; Monnet I; Rouquette I; Fraboulet-Moreau S; Lemoine A; Pouessel D; Mosser J; Vaylet F; Langlais A; Missy P; Morin F; Moro-Sibilot D; Cadranel J; Barlesi F; Beau-Faller M;
Ann Oncol; 2017 Nov; 28(11):2715-2724. PubMed ID: 28945865
[TBL] [Abstract][Full Text] [Related]
8. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
9. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
10. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
Li C; Jia R; Liu H; Zhang B; Wang C
Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
[TBL] [Abstract][Full Text] [Related]
11. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Reale ML; Chiari R; Tiseo M; Vitiello F; Barbieri F; Cortinovis D; Ceresoli GL; Finocchiaro G; Romano GD; Piovano PL; Del Conte A; Borra G; Verderame F; Scotti V; Nonnis D; Galetta D; Sergi C; Migliorino MR; Tonini G; Cecere F; Berardi R; Pino MS; Martelli O; Gelibter A; Carta A; Vattemi E; Pagano M; Zullo A; Ferrari S; Rossi A; Novello S
Lung Cancer; 2020 Feb; 140():71-79. PubMed ID: 31884129
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
19. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
20. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
